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Matsumura and colleagues have presented a series of patients
undergoing carotid artery stenting (CAS) with remarkably low
morbidity, specifically a death or stroke rate of 1.8%. However,
some study characteristics make the results perhaps less likely to
reflect expectations in practice.
First, results were compared against the legacy carotid endar-
terectomy (CEA) trials, including North American Symptomatic
Carotid Endarterectomy Trial (NASCET) and Asymptomatic Ca-
rotid Atherosclerosis Study (ACAS) conducted more than 20 years
ago and possibly not reflective of current results. Indeed, surgical
arm results in Carotid Revascularization Endarterectomy versus
Stenting Trial (CREST) were even better than in the legacy trials1
and CEA results have likely continued to improve since the legacy
trials.
Second, 86% of patients were asymptomatic. As impressive as
the results are, neurologic morbidity was still higher than for CEA
in ACAS from 20 years ago. Furthermore, the benefit of CEA over
medical treatment in the asymptomatic trials was marginal. Medi-
cal treatment of atherosclerosis has changed dramatically since
those studies and may have made CEA or carotid artery stenting
(CAS) irrelevant for asymptomatic disease. It is time for a new trial
of best medical therapy vs CEA and CAS in asymptomatic patients.
Third, 17% of patients were treated for recurrent stenosis.
Such patients were excluded from the legacy trials and, more
importantly, there is no evidence that recurrent stenosis is associ-
ated with the same stroke risk as primary carotid bifurcation
atherosclerosis. On the contrary, only 1 of 136 patients with
recurrent stenosis after CEA in ACAS had symptoms2 and the
majority of such patients may not need any intervention.3
Finally, 30% of the patients were octogenarians. The low
morbidity in the current study is truly astounding, given the high
proportion of octogenarians, and is discrepant from virtually all of
the single center and even randomized CAS trials, including
SPACE,4 EVA-3S,5 ICSS,6 and CREST.7 Furthermore, age 80
years was the sole reason why many of these patients were consid-
ered high risk for CEA in the current study, but results in the
published literature, admittedly subject to publication bias, sug-
gest that CEA is no higher risk in selected octogenarians than in
younger patients.8 Dr Matsumura and colleagues seem to have
avoided this morbidity in their octogenarian CAS patients and we
would all like to know how they achieved this. However, it is
questionable whether carotid intervention is appropriate for any
asymptomatic octogenarian because of limited life expectancy.9
The increasing cost of CEA per quality adjusted life year associated
with increasing age is likely to be even more unfavorable for CASecause the direct costs are clearly higher than for CEA, at least in
he United States.
The challenge with CAS and other new technologies is often
o find appropriate contemporaneous benchmarks against which
he new technology can be compared. Contemporary morbidity
ates for CEA and CAS are very low, low enough that any statistically
ignificant difference may be clinically irrelevant. Thus, the choice of
EA or CASmay bemade on financial grounds in the near future. In
ur hospital, and I suspect most hospitals in the United States, CEA
till wins that contest hands down.
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